PPPrasad Pofali

Prasad Pofali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Prasad Pofali has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exosome as a Natural Gene Delivery Vector for Cancer Treatment

    by Prasad Pofali, Adrita Mondal, Vaishali Londhe

    Background: Current gene therapy vectors such as viral, non-viral, and bacterial vectors, which are used for cancer treatment, but there are certain safety concerns and stability issues of these conventional vectors. Exosomes are the vesicles of size 40-100 nm secreted from multivesicular bodies into the extracellular environment by most of the cell types in-vivo and in-vitro. As a natural nanocarrier, exosomes are immunologically inert, biocompatible, and can cross biological barriers like the blood-brain barrier, intestinal barrier, and placental barrier. Objective: This review focusses on the role of exosome as a carrier to efficiently deliver a gene for cancer treatment and diagnosis. The methods for loading of nucleic acids onto the exosomes, advantages of exosomes as a smart intercellular shuttle for gene delivery and therapeutic applications as a gene delivery vector for siRNA, miRNA and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and also the limitations of exosomes as a gene carrier are all reviewed in this article. Methods: Mostly, electroporation and chemical transfection are used to prepare gene loaded exosomes. Results: Exosome-mediated delivery is highly promising and advantageous in comparison to the current delivery methods for systemic gene therapy. Targeted exosomes, loaded with therapeutic nucleic acids, can efficiently promote the reduction of tumor proliferation without any adverse effects. Conclusion: In the near future, exosomes can become an efficient gene carrier for delivery and a biomarker for the diagnosis and treatment of cancer.


  • Synthesis and antibacterial activity of water-dispersible silver nanoparticles via micellar nanoreactors

    by Prasad Pofali, Seema Shirolikar, Lalit Borde, Aditya Pattani, Prajakta Dandekar, Ratnesh Jain

    We have synthesized silver nanoparticles (AgNPs) using micelles of sugar fatty acid ester by dissolving the surfactant in a mixture of iso-octane and n-butanol, with solid-liquid extraction. Highly concentrated, water-dispersible AgNPs were obtained after thorough washing with alcohol, to remove excess of sucrose fatty acid ester DK SS and salt, followed by drying. The particles were characterized for their size, morphology and crystallinity using UV-Visible spectrophotometry, Transmission Electron Microscopy and X-ray diffractometry. Antibacterial study, confirmed the activity of nanoparticles against E. coli, P. aeruginosa and S. aureus, which causes diseases including diarrhoea and several life-threatening infections. Antibacterial activity of E. coli and P. aeruginosa was found to be 2.5 fold and for S. aureus 1.6 fold compared to 50 ppm conc. of Silver Nitrate. Our method of producing nanoparticles is employed as a platform technology for synthesizing other inorganic nanoparticles. This is the first report discussing the use of micellar carriers for obtaining silver nanopowder, to the best of our knowledge, which has the potential to overcome limitations during fabrication of AgNPs using reverse/inverse micelles. Our method yielded nano-sized, water-dispersible AgNPs via an easy and economic approach. The one-pot approach possesses advantages in terms of cost and simplicity, as compared with traditional methods of producing powdered AgNPs using energy intensive and expensive techniques like lyophilisation. The developed method, thus, possesses immense potential for commercial synthesis of AgNPs.


  • Gene therapy for bone tissue engineering

    by Young-Dong Kim, Prasad Pofali, Tae-Eun Park, Bijay Singh, Kihyun Cho, Sushila Maharjan, Prajakta Dandekar, Ratnesh Jain, Yun-Jaie Choi, Rohidas Arote, et al.

    Gene therapy holds a great promise and has been extensively investigated to improve bone formation and regeneration therapies in bone tissue engineering. A variety of osteogenic genes can be delivered by combining different vectors (viral or non-viral), scaffolds and delivery methodologies. Ex vivo & in vivo gene enhanced tissue engineering approaches have led to successful osteogenic differentiation and bone formation. In this article, we review recent advances of gene therapy-based bone tissue engineering discussing strengths and weaknesses of various strategies as well as general overview of gene therapy.


  • Drug‐conjugated polymers as gene carriers for synergistic therapeutic effect

    by P. A. Pofali, B. Singh, P. Dandekar, R. D. Jain, S. Maharjan, Y. J. Choi, R. B. Arote, C. S. Cho

    The ability to safely and effectively transfer gene into cells is the fundamental goal of gene delivery. In spite of the best efforts of researchers around the world, gene therapy has limited success. This may be because of several limitations of delivering gene which is one of the greatest technical challenges in the modern medicine. To address these issues, many efforts have been made to bind drugs and genes together by polymers for co‐delivery to achieve synergistic effect. Usually, binding interaction of drugs with polymers is either physical or chemical. In case of drug‐polymer physical interaction, the efficiency of drugs generally decreases because of separation of drugs from polymersin vivowhenever it comes in contact with charged biofluid/s or cells. While chemical interaction of drug–polymer overcomes the aforementioned obstacle, several problems such as steric hindrance, solubility, and biodegradability hinder it to develop as gene carrier. Considering these benefits and pitfalls, the objective of this review is to discuss the possible extent of drug‐conjugated polymers as safe and efficient gene delivery carriers for achieving synergistic effect to combat various genetic disorders. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 698–711, 2016.


  • siRNA-Based Therapies for Pulmonary Diseases

    by Uday Koli, R. Akhil Krishnan, Prasad Pofali, Ratnesh Jain, Prajakta Dandekar

    Various delivery strategies, involving siRNA as a therapeutic tool for gene silencing, have been highlighted through several investigations all over the world. One such medical target, where the siRNA-based therapies have been immensely explored and have met with considerable success, is the area of pulmonary disorders. Lung diseases have presented themselves as attractive targets for studying siRNA-mediated cures due to their widespread persistence and lethality. Another interesting feature in this case is that the lung is accessible to therapeutic agents via multiple administration routes including the nasal, oral and intravenous routes. Recent advances in pulmonary delivery highlight the exploitation of all these routes for administration of siRNA-based therapies, particularly by employing non-viral carriers like nanoparticles. Through this manuscript we aim to provide a comprehensive overview of the most important and the latest developments in non-viral siRNA delivery for lung diseases. We have focused our discussion on the diverse systems, which have been investigated for a plethora of pulmonary disorders, ranging from inflammatory conditions like asthma and COPD, to infectious diseases like tuberculosis, and to lung cancer. An overview of the preclinical and clinical investigations conducted in this area has also been presented to the readers. While a variety of these systems have been found to be promising in pre-clinical studies, their successful transition as therapeutics will ultimately depend upon their clinical safety and efficacy, as well as the specificity of the carriers and methods employed for their administration.